{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:23:12Z","timestamp":1791328992204,"version":"4.3.1"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T00:00:00Z","timestamp":1410998400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0003169","type":"journal-article","created":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T18:05:04Z","timestamp":1411063504000},"page":"e3169","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":44,"title":["Efficacy and Safety of Amphotericin B Emulsion versus Liposomal Formulation in Indian Patients with Visceral Leishmaniasis: A Randomized, Open-Label Study"],"prefix":"10.1371","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct00876824","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Shyam","family":"Sundar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandreshwar Prasad","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara Kant","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya Nand Ravi","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neena","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra Shekhar","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnawaz","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,9,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4269\/ajtmh.2010.10-0156","article-title":"Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India","volume":"83","author":"PK Sinha","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"ref2","unstructured":"Leishmaniasis: Epidemiology and access to medicines. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/leishmaniasis\/resources\/Leishmaniasis_worldwide_epidemiological_and_drug_access_update.pdf\" xlink:type=\"simple\">http:\/\/www.who.int\/leishmaniasis\/resources\/Leishmaniasis_worldwide_epidemiological_and_drug_access_update.pdf<\/ext-link>. Accessed 30 July 2013."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"778","DOI":"10.4269\/ajtmh.12-0442","article-title":"Visceral leishmaniasis prevalence and associated risk factors in the saran district of Bihar, India, from 2009 to July of 2011","volume":"88","author":"D Perry","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1473-3099(10)70011-6","article-title":"Combination therapy for visceral leishmaniasis","volume":"10","author":"J van Griensven","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-3156.2001.00778.x","article-title":"Drug resistance in Indian visceral leishmaniasis","volume":"6","author":"S Sundar","year":"2001","journal-title":"Trop Med Int Health"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/519690","article-title":"Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis","volume":"196","author":"SK Bhattacharya","year":"2007","journal-title":"J Infect Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJM199912093412403","article-title":"Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis","volume":"341","author":"TK Jha","year":"1999","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4269\/ajtmh.2011.10-0661","article-title":"Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh","volume":"85","author":"M Rahman","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"347","author":"S Sundar","year":"2002","journal-title":"N Engl J Med"},{"key":"ref10","first-page":"733","article-title":"Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management","volume":"3","author":"S Sundar","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/cid\/cis474","article-title":"Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use","volume":"55","author":"S Sundar","year":"2012","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"645203","DOI":"10.1155\/2011\/645203","article-title":"Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India","volume":"2011","author":"PK Sinha","year":"2011","journal-title":"J Trop Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/600105","article-title":"Highly effective oral amphotericin B formulation against murine visceral leishmaniasis","volume":"200","author":"KM Wasan","year":"2009","journal-title":"J Infect Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/bmj.323.7310.419","article-title":"Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial","volume":"323","author":"S Sundar","year":"2001","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/377542","article-title":"Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study","volume":"37","author":"S Sundar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/14728214.2012.748036","article-title":"Liposomal amphotericin B as a treatment for human leishmaniasis","volume":"17","author":"M Balasegaram","year":"2012","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"700","DOI":"10.4269\/ajtmh.2009.80.700","article-title":"Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis","volume":"80","author":"S Sundar","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/j.1365-3156.2008.02128.x","article-title":"Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar","volume":"13","author":"S Sundar","year":"2008","journal-title":"Trop Med Int Health"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e1973","DOI":"10.1371\/journal.pntd.0001973","article-title":"Treatment of visceral leishmaniasis: model-based analyses on the spread of antimony-resistant L. donovani in Bihar, India","volume":"6","author":"A Stauch","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1517\/14728210903153862","article-title":"Developments in the treatment of visceral leishmaniasis","volume":"14","author":"ML den Boer","year":"2009","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/380971","article-title":"Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations","volume":"38","author":"S Sundar","year":"2004","journal-title":"Clin Infect Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrmicro1748","article-title":"Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?","volume":"5","author":"F Chappuis","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1179\/136485910X12786389891641","article-title":"Socio-economic aspects of neglected diseases: sleeping sickness and visceral leishmaniasis","volume":"104","author":"M Boelaert","year":"2010","journal-title":"Ann Trop Med Parasitol"},{"key":"ref24","first-page":"38","article-title":"Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India","volume":"128","author":"CP Thakur","year":"2008","journal-title":"Indian J Med Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"959","DOI":"10.4269\/ajtmh.2012.11-0467","article-title":"Clinical epidemiologic profile of a cohort of post-kala-azar dermal leishmaniasis patients in Bihar, India","volume":"86","author":"VN Das","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e2611","DOI":"10.1371\/journal.pntd.0002611","article-title":"Post Kala-Azar dermal leishmaniasis following treatment with 20 mg\/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India","volume":"8","author":"S Burza","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"ref27","unstructured":"World Health Organization Control of the leishmaniases: Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22\u201326 March 2010. WHO technical report series; no. 949. Geneva: WHO."},{"key":"ref28","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1099\/jmm.0.46574-0","article-title":"Visceral leishmaniasis\/human immunodeficiency virus co-infection in India: The focus of two epidemics","volume":"55","author":"P Mathur","year":"2006","journal-title":"J Med Microbiol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e2195","DOI":"10.1371\/journal.pntd.0002195","article-title":"Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: A systematic review with indirect comparison","volume":"7","author":"GF Cota","year":"2013","journal-title":"PLoS Negl Trop Dis"}],"container-title":["PLoS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0003169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T06:39:07Z","timestamp":1589006347000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0003169"}},"subtitle":[],"editor":[{"given":"Elodie","family":"Ghedin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,9,18]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,9,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0003169","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,18]]}}}